Selecting here opens the current stored cards. The pinned link below records their fingerprints. Do not enter patient information in links or searches.
Share or print this source review
1 local source card selected. Local card fingerprints checked where supplied. This is not an original-document hash, source-currency guarantee or clinical approval. Record-level cautions below are the current library's cautions, not a frozen prior version.
Copy is optional; the link can be selected and copied manually. No patient data or dose decision is collected.
Clinical context remains essential
Independent clinical review is pending. Confirm indication, exact formulation/route, population, renal measure and units, kidney-function stability, dialysis prescription, interacting drugs, monitoring and source revision. An RX mirror and its original label are not independent corroboration. Missing disagreement notes do not certify agreement.
Check source scope before reading a dose
SAVELLA: selected primary-label renal guidance and limits
Product / population
Adult oral SAVELLA for fibromyalgia; not levomilnacipran extended-release.
Renal method
Estimated CrCl, mL/min; severe 5-29
Source revision
Revision date not captured in selected review; retrieval date is not revision date.
Retrieved
2026-11-07
Local review status
Selected sections checked against the identified source; not a complete monograph or independent clinician approval.
Documented differences and cautions on this drug
All record notes are retained here, including notes about sources not selected in this review.
SAVELLA: source applicability and renal evidence limits
Use the intact renal-dosing section, not the malformed moderate-renal PK range in the mirror. Reduced maintenance and initial titration are separate instructions.
What to reconcile: Do not skip titration or abruptly stop extended treatment.
DailyMed / product prescribing information · Adult oral SAVELLA for fibromyalgia; not levomilnacipran extended-release.
Renal method: Estimated CrCl, mL/min; severe 5-29 Source date: Revision date not captured in selected review; retrieval date is not revision date. Retrieved: 2026-11-07
Dose or interval guidance. Use only the product, indication, renal metric and population described in this source.
Before using this finding
ESRD: not recommended. Mild: no adjustment; moderate: caution.
Dialysis evidence: No dialysis regimen established in selected content
Selected sections checked against the identified source; not a complete monograph or independent clinician approval.
Section 2.2; discontinuation context
Mild impairment requires no adjustment; use caution in moderate impairment. At CrCl 5-29 mL/min, reduce maintenance to 25 mg twice daily; depending on response it may increase to 50 mg twice daily. ESRD use is not recommended. This is maintenance guidance, not an instruction to skip initial titration. Monitor tolerability and taper after extended use.
This reference does not select a regimen. Complete the indication, measured/estimated renal function and trend, dialysis setting, source rationale, monitoring and reassessment plan in your institution's approved documentation system. Confirm the complete current source before adopting its regimen.
GlobalRPh Renal Dosing Master v7.4. Review the retrieval and revision dates attached to each source. Selecting a reference does not imply clinical verification.
